Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:Drilon A" with an ORCID

Alexander Drilon
No affiliation detected
12
Publications
3,168
Citations
View profile

Search results

1-25 of 263 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Reply to Comment on "Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to 'False' Decreases in Renal Function".
Chen MF, Wilhelm C, Drilon A, Gutgarts V
J Thorac Oncol, 19(11):e62-e63, 01 Nov 2024
Cited by: 0 articles | PMID: 39510707
Add to export list
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
Desilets A, Repetto M, Drilon A
Clin Transl Med, 14(10):e70017, 01 Oct 2024
Cited by: 0 articles | PMID: 39402859 | PMCID: PMC11473655
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Two decades of advances in clinical oncology - lessons learned and future directions.
Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Weichselbaum RR, Weller M, Wu YL
Nat Rev Clin Oncol, 21(11):771-780, 01 Oct 2024
Cited by: 0 articles | PMID: 39354161
Add to export list
Case report: dynamic personalized physiological monitoring in lung cancer using wearable data.
Bliss JW, Underwood WP, Carlson AM, Scott JM, Daly R, Li BT, Drilon A, Stetson P, Boutros PC, Jones LW
Front Oncol, 14:1420888, 04 Oct 2024
Cited by: 0 articles | PMID: 39429470 | PMCID: PMC11486691
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.
Murciano-Goroff YR, Hui AB, Araujo Filho JA, Hamilton EG, Chabon JJ, Moding EJ, Bonilla RF, Lebow ES, Gomez D, Rimner A, Ginsberg MS, Offin M, Kundra R, Allaj V, Norton L, Reis-Filho JS, Razavi P, Drilon A, Jones DR, [...] Diehn M
JCO Precis Oncol, 8:e2400216, 01 Sep 2024
Cited by: 1 article | PMID: 39231375
Add to export list
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, [...] Drilon A
Cancer Discov, OF1-OF20, 13 Sep 2024
Cited by: 1 article | PMID: 39269178
Add to export list
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.
Chen MF, Yang SR, Tao JJ, Desilets A, Diamond EL, Wilhelm C, Rosen E, Gong Y, Mullaney K, Torrisi J, Young RJ, Somwar R, Yu HA, Kris MG, Riely GJ, Arcila ME, Ladanyi M, Donoghue MTA, Rosen N, [...] Offin M
Clin Cancer Res, 30(17):3812-3823, 01 Sep 2024
Cited by: 0 articles | PMID: 38922339
Add to export list
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA
NPJ Precis Oncol, 8(1):184, 28 Aug 2024
Cited by: 0 articles | PMID: 39198549 | PMCID: PMC11358392
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Liu SY, Erazo T, Jee J, Arfe A, Gupta A, Pike LRG, Santini FC, Daly B, Schoenfeld A, Eichholz J, Johnson K, Martinez A, Sui J, Riaz N, Chang J, Yang SR, Travis W, Arcila ME, Guo J, [...] Li BT
Eur J Cancer, 210:114257, 14 Aug 2024
Cited by: 0 articles | PMID: 39151324
Add to export list
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA
J Clin Oncol, 42(27):3187-3195, 02 Aug 2024
Cited by: 4 articles | PMID: 39094065 | PMCID: PMC11404750
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA
NPJ Precis Oncol, 8(1):175, 08 Aug 2024
Cited by: 1 article | PMID: 39117775 | PMCID: PMC11310217
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF, Repetto M, Wilhelm C, Drilon A
Drugs, 84(9):1035-1053, 13 Jul 2024
Cited by: 0 articles | PMID: 38997570
Add to export list Review
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, [...] Awad MM
Cancer Discov, 14(8):1440-1456, 01 Aug 2024
Cited by: 1 article | PMID: 38564707 | PMCID: PMC11294820
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman AS, Begüm Bektaş A, Bradic M, Kang W, Chan E, Gogia P, Manova-Todorova K, Mata DA, Egger JV, Rizvi H, Socci ND, Kelly DW, Rosiek E, Meng F, Tam G, [...] Vanderbilt CM
J Clin Oncol, 42(28):3339-3349, 22 Jul 2024
Cited by: 1 article | PMID: 39038258
Add to export list
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.
Hong DS, Drilon A, Wirth LJ
Clin Adv Hematol Oncol, 22 Suppl 5(6):1-20, 01 Jul 2024
Cited by: 0 articles | PMID: 38953725
Add to export list Review
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer.
Hong DS, Drilon A, Wirth LJ
Clin Adv Hematol Oncol, 22 Suppl 5(6):16, 01 Jul 2024
Cited by: 0 articles | PMID: 38953729
Add to export list
Management of patients with NTRK fusion-positive lung cancer.
Drilon A
Clin Adv Hematol Oncol, 22 Suppl 5(6):5-9, 01 Jul 2024
Cited by: 0 articles | PMID: 38953727
Add to export list
Serial Cell-Free DNA Sequencing in <i>ROS1</i> Fusion-Positive Lung Cancers During Treatment With Entrectinib.
Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A
JCO Precis Oncol, 8:e2300721, 01 Jun 2024
Cited by: 0 articles | PMID: 38848521
Add to export list
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, [...] Cocco E
Br J Cancer, 131(3):601-610, 20 Jun 2024
Cited by: 0 articles | PMID: 38902532 | PMCID: PMC11300601
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Optimus-Era Dose Finding for Rare Cancers.
Murciano-Goroff YR, Devlin SM, Iasonos A, Drilon A
Cancer Discov, 14(6):909-914, 01 Jun 2024
Cited by: 0 articles | PMID: 38826101
Add to export list
NTRK gene fusion testing and management in lung cancer.
Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C
Cancer Treat Rev, 127:102733, 03 Apr 2024
Cited by: 1 article | PMID: 38733648
Add to export list Review
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski LA, Murray JC, Marrone KA, Scott SC, Houseknecht S, Falcon CJ, Evans P, Feliciano J, Hann CL, Ettinger DS, Smith KN, Anagnostou V, Forde PM, Brahmer JR, Levy B, [...] Lam VK
Cancer Res Commun, 4(3):786-795, 01 Mar 2024
Cited by: 0 articles | PMID: 38407352
Add to export list
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers
Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA
bioRxiv, 20 Jan 2024
Cited by: 0 articles | PPR: PPR790247
Add to export list Preprint
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, [...] TRIDENT-1 Investigators
N Engl J Med, 390(2):118-131, 01 Jan 2024
Cited by: 20 articles | PMID: 38197815
Add to export list
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, Carrero S, Dhaneshwar A, Fernandez N, Xu BW, Arcila ME, Zehir A, Syed A, Brannon AR, Rudolph JE, Paraiso E, Sabbatini PJ, Levine RL, Dogan A, [...] Chakravarty D
Cancer Discov, 14(1):49-65, 01 Jan 2024
Cited by: 35 articles | PMID: 37849038 | PMCID: PMC10784742
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 263 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:Drilon A" with an ORCID

Search results

Reply to Comment on "Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to 'False' Decreases in Renal Function".

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.

Two decades of advances in clinical oncology - lessons learned and future directions.

Case report: dynamic personalized physiological monitoring in lung cancer using wearable data.

Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.

Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.

Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers.

Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancer.

Management of patients with NTRK fusion-positive lung cancer.

Serial Cell-Free DNA Sequencing in <i>ROS1</i> Fusion-Positive Lung Cancers During Treatment With Entrectinib.

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.

Optimus-Era Dose Finding for Rare Cancers.

NTRK gene fusion testing and management in lung cancer.

Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.

Partnerships & funding

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:Drilon A" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Drilon A" with an ORCID